Structures of α-synuclein filaments from human brains with Lewy pathology

References 66

1. 1.
   Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease · 2014

   No notice
2. 2.

   Goedert M, Spillantini MG, Del Tredici K, Braak H. 100 years of Lewy pathology. Nature Rev Neurol. 2013;9:13-24.

   Not in our library10.1038/nrneurol.2012.242

3. 3.

   Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sørensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol. 2003;60:387-392.

   Not in our library10.1001/archneur.60.3.387

4. 4.
   Diagnosis and management of dementia with Lewy bodies · 2017

   No notice
5. 5.

   Fanciulli A, Wenning GK. Multiple system atrophy. N Engl J Med. 2015;372:249-263.

   Not in our library10.1056/nejmra1311488

6. 6.

   Schweighauser M, et al. Structures of α-synuclein filaments from multiple system atrophy. Nature. 2020;585:464-469.

   Not in our library10.1038/s41586-020-2317-6

7. 7.

   Polymeropoulos MH, et al. Mutation in the α-synuclein gene identified in families with Parkinson’s disease. Science. 1997;276:2045-2047.

   Not in our library10.1126/science.276.5321.2045

8. 8.

   Singleton AB, et al. α-Synuclein locus triplication causes Parkinson’s disease. Science. 2003;302:841.

   Not in our library10.1126/science.1090278

9. 9.

   Zarranz JJ, et al. The new mutation, E46K, of alpha-synuclein causes Parkinson’s disease and Lewy body dementia. Ann Neurol. 2004;55:164-173.

   Not in our library10.1002/ana.10795

10. 10.

    Nalls MA, et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease. Nature Genet. 2014;46:989-993.

    Not in our library10.1038/ng.3043

11. 11.

    Davidson WS, Jonas A, Clayton DF, George JM. Stabilization of α-synuclein secondary structure upon binding to synthetic membranes. J Biol Chem. 1998;273:9443-9449.

    Not in our library10.1074/jbc.273.16.9443

12. 12.

    Ueda K, et al. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci USA. 1993;90:11282-11286.

    Not in our library10.1073/pnas.90.23.11282

13. 13.

    Li HT, Du HN, Tang L, Hu J, Hu HY. Structural transformation and aggregation of human α-synuclein in trifluoroethanol: non-amyloid component sequence is essential and β-sheet formation is prerequisite to aggregation. Biopolymers. 2002;64:221-226.

    Not in our library10.1002/bip.10179

14. 14.

    Crowther RA, Jakes R, Spillantini MG, Goedert M. Synthetic filaments assembled from C-terminally truncated α-synuclein. FEBS Lett. 1998;436:309-312.

    Not in our library10.1016/s0014-5793(98)01146-6

15. 15.

    Conway KA, Harper JD, Lansbury PT. Fibrils formed in vitro from α-synuclein and two mutant forms linked to Parkinson’s disease are typical amyloid. Biochemistry. 2000;39:2525-2563.

    Not in our library10.1021/bi991447r

16. 16.
    Fiber diffraction of synthetic α-synuclein filaments shows amyloid-like cross-β conformation · 2000

    Not checked
17. 17.

    Miake H, Mizusawa H, Iwatsubo T, Hasegawa M. Biochemical characterization of the core structure of α-synuclein filaments. J Biol Chem. 2002;277:19213-19219.

    Not in our library10.1074/jbc.m110551200

18. 18.

    Mougenot AL, et al. Prion-like acceleration of a synucleinopathy in a transgenic mouse model. Neurobiol Aging. 2012;33:2225-2228.

    Not in our library10.1016/j.neurobiolaging.2011.06.022

19. 19.

    Luk KC, et al. Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science. 2012;338:949-953.

    Not in our library10.1126/science.1227157

20. 20.

    Masuda-Suzukake M, et al. Prion-like spreading of pathological α-synuclein in brain. Brain. 2013;136:1128-1138.

    Not in our library10.1093/brain/awt037

21. 21.

    Osterberg VR, et al. Progressive aggregation of α-synuclein and selective degeneration of Lewy inclusion-bearing neurons in a mouse model of parkinsonism. Cell Rep. 2015;10:1252-1260.

    Not in our library10.1016/j.celrep.2015.01.060

22. 22.

    Peelaerts W, et al. α-Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature. 2015;522:340-344.

    Not in our library10.1038/nature14547

23. 23.

    Peng C, et al. Cellular milieu imparts pathological α-synuclein strains in α-synucleinopathies. Nature. 2018;557:558-563.

    Not in our library10.1038/s41586-018-0104-4

24. 24.

    Prusiner SB, et al. Evidence for α-synuclein prions causing multiple system atrophy in humans with parkinsonism. Proc Natl Acad Sci USA. 2015;112:E5308-E5317.

    Not in our library10.1073/pnas.1514475112

25. 25.

    Tarutani A, Arai T, Murayama S, Hisanaga SI, Hasegawa M. Potent prion-like behaviors of pathogenic α-synuclein and evaluation of inactivation methods. Acta Neuropathol Commun. 2018;6:29.

    Not in our library10.1186/s40478-018-0532-2

26. 26.
    Parkinson’s disease and multiple system atrophy have distinct α-synuclein seed characteristics · 2019

    No notice
27. 27.
    Silver staining (Campbell-Switzer) of neuronal α-synuclein assemblies induced by multiple system atrophy and Parkinson’s disease brain extracts in transgenic mice · 2019

    Not checked
28. 28.

    Klingstedt T, et al. Luminescent conjugated oligothiophenes distinguish between α-synuclein assemblies of Parkinson’s disease and multiple system atrophy. Acta Neuropathol Commun. 2019;7:193.

    Not in our library10.1186/s40478-019-0840-1

29. 29.
    Structural heterogeneity of α-synuclein fibrils amplified from patient brain extracts · 2019

    No notice
30. 30.

    Lau A, et al. α-Synuclein strains target distinct brain regions and cell types. Nature Neurosci. 2020;23:21-31.

    Not in our library10.1038/s41593-019-0541-x

31. 31.

    Shahnawaz M, et al. Discriminating α-synuclein strains in Parkinson’s disease and multiple system atrophy. Nature. 2020;578:273-277.

    Not in our library10.1038/s41586-020-1984-7

32. 32.

    Ayers JI, et al. Different α-synuclein prion strains cause dementia with Lewy bodies and multiple system atrophy. Proc Natl Acad Sci USA. 2022;119:e2113489119.

    Not in our library10.1073/pnas.2113489119

33. 33.

    Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies. Proc Natl Acad Sci USA. 1998;95:6469-6473.

    Not in our library10.1073/pnas.95.11.6469

34. 34.

    Crowther RA, Daniel SE, Goedert M. Characterisation of isolated α-synuclein filaments from substantia nigra of Parkinson’s disease brain. Neurosci Lett. 2000;292:128-130.

    Not in our library10.1016/s0304-3940(00)01440-3

35. 35.

    Holec SAM, Liu SL, Woerman AL. Consequences of variability in α-synuclein fibril structure on strain biology. Acta Neuropathol. 2022;143:311-330.

    Not in our library10.1007/s00401-022-02403-w

36. 36.

    Zhao K, et al. Parkinson’s disease-related phosphorylation at Tyr39 rearranges α-synuclein amyloid fibril structure revealed by cryo-EM. Proc Natl Acad Sci USA. 2020;117:20305-20315.

    Not in our library10.1073/pnas.1922741117

37. 37.

    McGlinchey RP, Ni X, Shadish JA, Jiang J, Lee JC. The N-terminus of α-synuclein dictates fibril formation. Proc Natl Acad Sci USA. 2021;118:e2023487118.

    Not in our library10.1073/pnas.2023487118

38. 38.
    Two new polymorphic structures of human full-length alpha-synuclein fibrils solved by cryo-electron microscopy · 2019

    No notice
39. 39.

    Shi Y, et al. Structure-based classification of tauopathies. Nature. 2021;598:359-363.

    Not in our library10.1038/s41586-021-03911-7

40. 40.

    Tsuboi Y, Dickson DW. Dementia with Lewy bodies and Parkinson’s disease with dementia: Are they different? Parkinsonism Relat. Disord. 2005;11:S47-S51.

    Not in our library10.1016/j.parkreldis.2004.10.014

41. 41.

    Compta Y, et al. Lewy- and Alzheimer-type pathologies in Parkinson’s disease dementia: which is more important? Brain. 2011;134:1493-1505.

    Not in our library10.1093/brain/awr031

42. 42.

    Braak H, Del Tredici K. Neuroanatomy and pathology of sporadic Parkinson’s disease. Adv Anat Embryol Cell Biol. 2009;201:1-119.

    Not in our library

43. 43.

    Poggiolini I, et al. Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies. Brain. 2022;145:584-595.

    Not in our library10.1093/brain/awab431

44. 44.

    Candelise N, et al. Seeding variability of different alpha-synuclein strains in synucleinopathies. Ann Neurol. 2019;85:691-703.

    Not in our library10.1002/ana.25446

45. 45.
    The structural differences between patient-derived α-synuclein strains dictate characteristics of Parkinson’s disease, multiple system atrophy and dementia with Lewy bodies · 2020

    No notice
46. 46.
    Seeded assembly in vitro does not replicate the structures of α‐synuclein filaments from multiple system atrophy · 2021

    No notice
47. 47.

    Burger D, Fenyi A, Bousset L, Stahlberg H, Melki R. Cryo-EM structure of alpha-synuclein fibrils amplified by PMCA from PD and MSA patient brains. BioRxiv.

    Not in our library

48. 48.

    Frieg B, et al. α-Synuclein polymorphism determines oligodendroglial dysfunction. BioRxiv.

    Not in our library

49. 49.

    Sokratian A, et al. Structural and functional landscape of α-synuclein fibril conformations amplified from cerebrospinal fluid. BioRxiv.

    Not in our library

50. 50.

    Spillantini MG, Crowther RA, Jakes R, Cairns NJ, Lantos PL, Goedert M. Filamentous α-synuclein inclusions link multiple system atrophy with Parkinson’s disease and dementia with Lewy bodies. Neurosci Lett. 1998;251:205-208.

    Not in our library10.1016/s0304-3940(98)00504-7

51. 51.

    Woerman AL, et al. Familial Parkinson’s point mutation abolishes multiple system atrophy prion replication. Proc Natl Acad Sci USA. 2018;115:409-414.

    Not in our library10.1073/pnas.1719369115

52. 52.
    Assembly of recombinant tau into filaments identical to those of Alzheimer’s disease and chronic traumatic encephalopathy · 2022

    No notice
53. 53.
    Age-dependent formation of TMEM106B amyloid filaments in human brains · 2022

    No notice
54. 54.

    Goedert M, Spillantini MG, Cairns NJ, Crowther RA. Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms. Neuron. 1992;8:159-168.

    Not in our library10.1016/0896-6273(92)90117-v

55. 55.

    Giasson BI, et al. A panel of epitope-specific antibodies detects protein domains distributes throughout human α-synuclein in Lewy bodies of Parkinson’s disease. J Neurosci Res. 2000;59:528-533.

    Not in our library10.1002/(sici)1097-4547(20000215)59:4<528::aid-jnr8>3.0.co;2-0

56. 56.

    Perrin RJ, et al. Epitope mapping and specificity of the antialpha synuclein monoclonal antibody Syn-1 in mouse brain and cultured cell lines. Neurosci Lett. 2003;349:133-135.

    Not in our library10.1016/s0304-3940(03)00781-x

57. 57.

    Spina S, et al. The tauopathy associated with mutation +3 in intron 10 of Tau: characterization of the MSTD family. Brain. 2008;131:72-89.

    Not in our library10.1093/brain/awm280

58. 58.
    A Bayesian approach to beam-induced motion correction in cryo-EM single-particle analysis · 2019

    No notice
59. 59.

    Rohou A, Grigorieff N. CTFFIND4: fast and accurate defocus estimation from electron micrographs. J Struct Biol. 2015;192:216-221.

    Not in our library10.1016/j.jsb.2015.08.008

60. 60.
    Helical reconstruction in RELION · 2017

    No notice
61. 61.
    New tools for automated high-resolution cryo-EM structure determination in RELION-3 · 2018

    No notice
62. 62.
    Amyloid structure determination in RELION -3.1 · 2020

    No notice
63. 63.
    Estimation of high-order aberrations and anisotropic magnification from cryo-EM data sets in RELION -3.1 · 2020

    No notice
64. 64.
    MolProbity : all-atom structure validation for macromolecular crystallography · 2009

    No notice
65. 65.
    Current developments in Coot for macromolecular model building of Electron Cryo‐microscopy and Crystallographic Data · 2020

    No notice
66. 66.
    Cryo-EM single-particle structure refinement and map calculation using Servalcat · 2021

    No notice

Cited by papers we hold 4

• Misfolded protein oligomers: mechanisms of formation, cytotoxic effects, and pharmacological approaches against protein misfolding diseases · 2024
  No notice
• Molecular Crowding: The History and Development of a Scientific Paradigm · 2024
  No notice
• TDP-43 forms amyloid filaments with a distinct fold in type A FTLD-TDP · 2023
  No notice
• Disease-specific tau filaments assemble via polymorphic intermediates · 2023
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.